Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of ␣-interferon (␣-IFN) in patients not in CR when evaluated 4 months post-transplant. We report five of 13 evaluable patients undergoing allogeneic sibling BM or PBSC transplantation for MM between 1990 and 1997 who met the criteria for adjuvant ␣-IFN therapy. A starting dose of 3 MU × 3/week was commenced at median time of day +126 (range day +112-224) posttransplant and was well-tolerated. In contrast to other reports we observed no increased toxicity in terms of GVHD compared to those patients not receiving ␣-IFN therapy and only one patient treated with ␣-IFN has developed chronic GVHD. Durable CRs were achieved in two patients within 8 weeks of starting therapy whilst two other patients required a longer course of ␣-IFN to achieve CR (36 weeks and 30 weeks, respectively). One patient whose paraprotein was rapidly rising at the time of ␣-IFN therapy clinically relapsed despite 6 months of treatment. None of the patients who achieved CR following ␣-IFN therapy have relapsed and we conclude that ␣-IFN is a safe and effective adjuvant treatment for some patients in the achievement of CR following allogeneic transplantation for myeloma. Keywords: allogeneic transplantation; interferon; myeloma Allogeneic transplantation offers a chance of cure for young patients with multiple myeloma who have a sibling donor. However, recent analyses of outcome have been somewhat disappointing; in particular there has been a high transplant-related mortality (TRM) of 40-50% and a low CR rate. [1] [2] [3] In the EBMT series only 44% of patients achieved a complete remission and the overall survival at 4 years was 32%. 4 Likewise the Seattle data show a CR rate of 36% and a high early TRM of 35% by 100 days.
lower TRM and a high response rate in patients transplanted earlier in their disease. 5 The interferons (IFNs) are known to modulate a variety of cellular responses, exhibiting antitumour activity in a range of malignancies due to their growth inhibitory properties. 6 A number of studies have suggested that ␣-IFN may be a useful agent in the treatment of myelomatosis (reviewed in Ref. 7 ) and the addition of ␣-IFN maintenance therapy may prolong remissions following autologous transplantation. 8 In view of this and the fact that ␣-IFN can induce molecular remissions in patients relapsing following allogeneic transplantation for chronic myeloid leukaemia (CML), 9 we have explored its use as adjuvant therapy in patients with myeloma failing to achieve CR following allogeneic transplantation. In this setting, we hoped that ␣-IFN may have a dual effect, both by acting directly on residual myeloma cells and by augmenting the graft-versusmyeloma (GVM) effect of the allogeneic transplant, 10 thus providing an alternative to donor leucocyte infusions for these patients.
Patients and methods

Patients
Between 1990 and 1997, five of 14 evaluable patients (aged 40-59 years) receiving allogeneic transplants from sibling donors met the criteria for ␣-IFN therapy. Three of these patients had received bone marrow (one mismatched at one HLA-A locus) and two had received G-CSF-mobilised peripheral blood stem cells (PBSC). Four of the patients had been conditioned with melphalan (110 mg/m 2 ) and TBI (12 Gy in six fractions) and one received cyclophosphamide (60 mg/kg ϫ 2) and fractionated TBI. All five patients had received CsA as GVHD prophylaxis (with twice weekly assays to maintain a whole blood level of 95-200 ng/ml) together with MTX on days +1 (15 mg/m 2 ), +3, +6 and +11 (all 10 mg/m 2 ). In addition, the patient receiving a mismatched transplant also received in vivo T cell depletion using Campath 1G from day Ϫ5 to day Ϫ1. All patients had responsive disease and were in PR at the time of transplant having received one to three previous lines of chemotherapy. CsA therapy was tapered from day +50 and had been discontinued for at least 1 month prior to starting ␣-IFN therapy. Platelet counts at initiation of ␣-IFN therapy ranged from 142 to 246 ϫ 10 9 /l (see Table 1 ). The remaining eight patients had all achieved CR by 4 months posttransplant and have remained in CR with a median follow up of 3.6 months (range 4 months to 6.6 years). /l, and GVHD of grade 1 or less, they were commenced on ␣-IFN therapy.
640
Dosage and duration of ␣-IFN
␣-IFN was commenced at a standard starting dosage of 3 MU ϫ 3/week with the potential of reducing to ϫ 2/week if necessary (exacerbation of GVHD or development of significant thrombocytopenia of Ͻ50 ϫ 10 9 /l). Treatment was continued until the achievement of CR or until disease progression occurred.
IgH PCR
IgH PCR was used in informative patients for MRD monitoring. DNA was prepared from bone marrow samples using a Nucleon DNA extraction kit (Scottlab, Coatbridge, UK).
IgH rearrangements were detected using a fluorescent PCR technique. This utilised a common JH primer labelled with a yellow fluorochrome together with a second informative primer from either the framework 3 or the framework 1 region of the gene. The PCR products were analysed using an Applied Biosystems (Perkin-Elmer, Warrington, UK) DNA sequencer whose computer software converts the fluorescent gel image into an 'electrophoretogram' which consists of a number of peaks whose height corresponds to the fluorescence intensity on the gel. A polyclonal pattern appears as a number of indistinct peaks arranged in a normal distribution whilst clonal rearrangements appear as distinct peaks either alone or within a polyclonal background. Size standards are loaded into each lane which enables product sizing to within 1 base pair and the sensitivity of this PCR method is 10
Ϫ4
.
Results
Toxicity and GVHD
␣-IFN was tolerated by all five patients and no significant haematological toxicity was observed. Four patients had no evidence of GVHD at the time of starting ␣-IFN (although one had experienced a previous episode of grade 1 acute GVHD which had fully resolved) and remained free of GVHD during and after ␣-IFN therapy. One patient, who had mild grade 1 GVHD affecting the skin at the time of ␣-IFN therapy, had an exacerbation of this during treatment requiring dose reduction to 3 MU ϫ 2/week and commencement of oral corticosteroids. This patient has gone on to develop chronic GVHD affecting the skin which is controlled by continuing immunosuppression (see Table 2 ). This GVHD risk compares favourably to that of the remaining nine evaluable patients who underwent allogeneic transplantation for myeloma during the same time period and did not receive ␣-IFN, in whom two cases of grade 1 acute GVHD were seen with one patient going on to develop chronic GVHD.
Outcome
All patients receiving ␣-IFN had evidence of continuing plasma cell infiltration in the bone marrow and/or residual monoclonal paraprotein or light chains at the time of treatment which commenced at a median time of day +126 posttransplant (range day +112-+224). In contrast the remaining nine patients receiving allogeneic transplants for myeloma had all achieved CR by a median of day +68 posttransplant (range day +21-+110). The effect of ␣-IFN therapy on these five patients is shown schematically in Figure  1 . Patients 2 and 4 achieved CR within 8 weeks of starting ␣-IFN therapy with complete disappearance of the monoclonal band. One of these patients had a monoclonal IgH rearrangement which also disappeared during ␣-IFN therapy indicating a molecular remission. Both patients remain in CR at 61 months and 18 months, respectively, despite cessation of the ␣-IFN soon after CR was achieved. Patients 3 and 5, however, required a longer course of ␣-IFN, achieving CR after 36 and 30 weeks of therapy, respectively, and had a gradual disappearance of the monoclonal band during treatment. Both of these patients remain disease free at 42 months and 15 months, respectively, and in addition patient 5 has achieved a molecular remission since starting ␣-IFN therapy. This patient had a framework 1 VH2 IgH rearrangement detectable as a 349 base pair peak prior to transplantation which was still detectable among other oligoclonal bands at 4 months post-transplant prior to commencement of ␣-IFN, but following treatment repeated analysis has shown that a polyclonal pattern of IgH rearrangement has returned (see Figure 2) . Interestingly, in this patient disappearance of the monoclonal IgH rearrangement preceded disappearance of the serum paraprotein by a couple of months suggesting that molecular monitoring is a more sensitive indicator of current disease status in such patients. The remaining patient (patient 1) had a rapidly rising paraprotein level at the time of starting ␣-IFN which was commenced later than in the other patients at 7 months post-transplant and this patient clinically relapsed despite 6 months of therapy.
Discussion
The role of immunotherapy following allogeneic transplantation is being increasingly explored in an attempt to augment graft-versus-tumour effects. The use of donor T cells in the treatment of early relapse of CML is now widely accepted, and following recent evidence supporting the existence of graft-versus-myeloma (GVM) effects, 10 similar strategies are being utilised for the treatment of early relapse of multiple myeloma following allogeneic transplantation. 11, 12 Since ␣-IFN is known to up-regulate the expression of HLA class II molecules and stimulate the activity of NK cells, 13 its use following allogeneic transplantation may be an alternative means of stimulating graftversus tumour effects. Indeed, ␣-IFN has been successfully used in the treatment of patients with relapsed CML posttransplant. 9 One drawback to this approach is the potential increased risk of significant GVHD when using ␣-IFN in the post-transplant setting. Although studies using ␣-IFN post-transplant for relapsed CML and in poor risk acute leukaemia have not demonstrated an increased incidence of GVHD, 9,14 a previous pilot study using ␣-IFN following allogeneic transplantation for myeloma showed a significant dose-related increase in the risk of GVHD which limited its usefulness. 15 In contrast to this study we observed no significant increased risk of GVHD in five patients treated with standard dose ␣-IFN following allogeneic transplantation for myeloma. This difference may be related to the timing of the ␣-IFN which was started at an earlier time post-transplant in the seven previously reported cases (median 3 months, minimum 2 months) as compared to a median time of day +126 post-transplant (minimum day +112) in the patients treated at our centre. In addition, CsA prophylaxis had already been withdrawn without stimulating significant GVHD prior to the commencement of ␣-IFN in our patients. The IFN therapy was discontinued as soon as CR was achieved in these patients since we considered that the desired GVM effect had been accomplished and that continuing therapy may have led to an increased risk of GVHD. The use of ␣-IFN was associated with the achievement of durable CRs in four of the patients treated, and loss of a previously detectable IgH rearrangement was seen whilst on treatment in two of these patients. The fifth patient, who commenced ␣-IFN therapy late (Ͼ6 months posttransplant) in the presence of a rapidly rising paraprotein, showed evidence of disease progression and clinically relapsed despite 6 months of treatment. This again suggests that the timing of ␣-IFN therapy post-allogeneic transplantation may be critical in achieving a response without unwanted GVHD.
It is of interest that in patient 5 the disappearance of this molecular marker preceded eradication of the paraprotein by a couple of months, indicating the slow clearance of immunoglobulin and suggesting that molecular monitoring is a more sensitive indicator of current disease status in these patients post-transplant.
It may be argued that the achievement of CR in these patients was not related to the ␣-IFN therapy, but was a late effect of the transplant itself. However these patients appeared to have evidence of residual disease with a stable paraprotein pre-IFN therapy despite an initial fall posttransplant. This was in contrast to the other patients transplanted for myeloma during this time period in whom the paraprotein fell steadily post-transplant and who achieved CR at a median of 68 days post-transplant (range 21-110 days). Other groups have also reported a similar early achievement of CR post-allogeneic transplantation with all five patients studied by Bird et al 16 achieving CR within 3 months of transplantation, whilst the Vancouver group reported that eight of 13 patients achieving CR after allogeneic transplantation did so within 100 days post-transplant. 17 In this latter study, five patients had delayed achievement of CR occurring 6 months to 2 years posttransplant. It is interesting to note that one of these patients who achieved a delayed CR did so after receiving 8 months of ␣-IFN therapy for concomitant hepatitis C, and another of these patients with a delayed CR went on to develop progressive disease. 17 Thus although it is possible for delayed durable CRs to occur following allogeneic transplantation for myeloma, the majority of patients who achieve CR do so within 6 months of treatment. Since the achievement of CR is an important determinant of outcome following allografting in myeloma, 1 we feel that it is important to maximise response rates. An alternative approach would be to give donor leucocyte infusions but this has been associated with a high incidence of GVHD. 12 We have found the use of ␣-IFN to be well-tolerated in this setting and its use certainly seemed to be associated with responses in patients whose paraprotein appeared to have plateaued prior to starting therapy. Whether the activity of IFN is attributable to the induction of a graft-versus-myeloma effect remains uncertain. However, in only one case was the response clearly associated with induction of GVHD.
In summary we conclude that ␣-IFN may safely be used to assist the achievement of CR for some patients following allogeneic transplantation for multiple myeloma and can be considered as an alternative to donor leucocyte infusions to augment responses in those patients not in remission when assessed at 4-6 months post-transplant.
